Elafibranor Improves Biochemical Response and Prognostic Scores in Primary Biliary Cholangitis
In the phase III ELATIVE trial, 52 weeks of elafibranor improved biochemical response rates across all criteria and favorably modified ...
Tag: elafibranor
